Company intelligence / Profile preview
Evolutionary Biologics
New Jersey, United Statesevobiologics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Company develops regenerative biologic products including MSC-derived exosomes and tissue-based products for aesthetics, orthopedics, and wellness; products marketed as FDA compliant but FDA issued warning in December 2024 stating they are unapproved new drugs and unlicensed biologics.[6]
- Therapeutic areas
- OtherNeurologyDermatologyRheumatologyMen's Health
- Modalities
- Exosome-based therapyCell therapyBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Evolutionary Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evolutionary Biologics.